Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Aug 10;34(23):2797.
doi: 10.1200/JCO.2016.66.4458. Epub 2016 Jun 20.

Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma?

Jen-Fu Yang  1 , Cheng-Hsiang Lo  1 , Wen-Yen Huang  2
Affiliations
Comment

Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma?

Jen-Fu Yang et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply to Yang et al and De Bari et al.
    Wahl DR, Tao Y, Schipper M, Lawrence TS, Feng M. Wahl DR, et al. J Clin Oncol. 2016 Aug 10;34(23):2799. doi: 10.1200/JCO.2016.67.7492. Epub 2016 Jun 20. J Clin Oncol. 2016. PMID: 27325853 Free PMC article. No abstract available.

Comment on

References

    1. Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2015;34:452–459. - PMC - PubMed
    1. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421–430. - PubMed
    1. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. - PubMed
    1. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062–1069. - PMC - PubMed
    1. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55:1309–1316. - PubMed

LinkOut - more resources